NCT05787535View on ClinicalTrials.gov

HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor

PHASE1UnknownINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

March 21, 2023

Primary Completion Date

February 28, 2025

Study Completion Date

September 30, 2025

Conditions
Cervical CancerHead and Neck Squamous Cell CarcinomaOropharyngeal CancerVagina TumorCarcinoma of PenisAnal CarcinomaCarcinoma of Vulva
Interventions
DRUG

Fludarabine + Cyclophosphamide

Fludarabine: 25mg/m²/day×3days; Cyclophosphamide: 250mg/m²/day×3 days

BIOLOGICAL

HRYZ-T101 TCR-T Cell

On day 1, the TCR-T cells will be administered one time.

Trial Locations (1)

200120

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

Sponsors

Lead Sponsor

HRYZ Biotech Co.
All Listed Sponsors
lead

HRYZ Biotech Co.

INDUSTRY

NCT05787535 - HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor | Biotech Hunter | Biotech Hunter